“We are replacing or repairing the devices related to the Respironics field action as fast as possible and are continuing to update patients and customers about the progress of the program,” David Ferguson, business leader of Philips Respironics, said in the May 24 statement. “More than 1,000 of our colleagues are working around the clock on every aspect of the remediation.”
The FDA is not changing its initial recommendations from June 2021, according to the May 19 notice.
